Latest news Diaccurate Acquires Clinical Stage Sole-in-Class Targeted Cancer Therapy from Merck KGaA, Darmstadt, Germany September 8, 2021 Diaccurate introduces its world-leading Scientific Advisory Board July 8, 2021 Diaccurate acquires Biokinesis to create a sole-in-class biotech player in oncology and immunotherapy January 12, 2021 See all press releases Home Media Selected media Diaccurate Adds Merck PAM Inhibitor to Oncology/Immunology Pipeline September 9, 2021 Merck KGaA entrusts secretive startup with a mid-stage cancer drug targeting master signaling pathway September 8, 2021 Could HIV be cured by tackling ‘bumpy’ CD4 cells? France’s Diaccurate wants to find out August 12, 2021 Media contact details MC Services (US & EU) Anne Hennecke +49 211 529252 22 Simone Neeten +49 211 52925217 diaccurate@mc-services.eu ATCG Partners (France) Jérôme Marino +33 (0)6 11 56 98 91 Marie Puvieux +33 (0)9 52 78 85 08 diaccurate@atcg-partners.com
Diaccurate Acquires Clinical Stage Sole-in-Class Targeted Cancer Therapy from Merck KGaA, Darmstadt, Germany September 8, 2021
Diaccurate acquires Biokinesis to create a sole-in-class biotech player in oncology and immunotherapy January 12, 2021
Merck KGaA entrusts secretive startup with a mid-stage cancer drug targeting master signaling pathway September 8, 2021
Could HIV be cured by tackling ‘bumpy’ CD4 cells? France’s Diaccurate wants to find out August 12, 2021
